171350-05-3

Upstream product

• 51067-38-0 4-phenoxyphenylboronic acid 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 21473-02-9 4-phenoxyphenylmagnesium bromide 
• 171350-04-2 N-tert-Butyloxycarbonyl-4-hydroxy-4-(4-phenoxyphenyl)piperidine 

Downstream Products

• 181206-68-8 (E)-1-[3-(4-hydroxy-3-methoxyphenyl)-2-propenyl]-4-(4-phenoxyphenyl)piperidine 
• 181211-92-7 (E)-1-[3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl]-4-(4-phenoxyphenyl)-1,2,3,6-tetrahydropyridine 
• 181206-69-9 1-[2-(4-fluorophenyl)oxyethyl]-4-(4-phenoxyphenyl)-1,2,3,6-tetrahydropyridine 
• 725739-61-7 4-(4-phenoxy-phenyl)-3,6-dihydro-2H-pyridine-1-sulfonyl chloride 
• 181207-55-6 4-(4-Phenoxyphenyl)piperidine 

Relevant academic research and scientific papers

Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs

A novel series of TNF inhibitors was identified based on the screening of existing MMP inhibitor libraries. Further SAR optimization led to the discovery of a novel lead compound. Its synthesis, efficacy in experimental animal models, and pharmacokinetic

Synthesis and biological evaluation of new 4-arylpiperidines and 4-aryl-4-piperidinols: dual Na+ and Ca2+ channel blockers with reduced affinity for dopamine D2 receptors

A series of novel 4-arylpiperidines and 4-aryl-4-piperidinols (2a-f, 3a-f and 4a-f) was synthesized and evaluated for blocking effects on both neuronal Na+ and T-type Ca2+ channels and binding affinity for dopamine D2 receptors. Most of the compounds blockaded both ion channels with potency greater than or equal to flunarizine 1a which was adopted as a reference standard. In addition, these compounds had significantly reduced affinity for dopamine D2 receptors which is common in this class of structure. Compounds 2a-f, 3a-f and 4a-f exhibited potent anticonvulsant effects following systemic (ip) administration on audiogenic seizures in DBA/2 mice, indicating their excellent brain permeability. The neuroprotective activity of 2a, 3a and 4a was also assessed in a transient middle cerebral artery occlusion (MCAO) model. These compounds significantly reduced neuronal damage without affecting ischemic hyperthemia, while flunarizine 1a produced only minor reductions. In particular, 4a had 1.7-fold the potency in this MCAO method but only 1/20 the affinity for dopamine D2 receptor of 1a. The superposition of 2a, 3a and 4a on the basis of analyses of systematic conformation and similar structure has revealed that the cinnamyl, phenacyl and phenoxypropanol groups are likely to be structurally and biologically equivalent. Moreover, the superposition of 2a and 2f shows that diphenyl ether and biphenyl groups occupy a similar space, suggesting that both groups act as a bioisostere for the blockade of ion channels; however, this is not the case for dopamine D2 receptors since only biphenyl compounds such as 2f had high affinitity similar to flunarizine 1a. Compound 4a (SUN N5030) has a good pharmacological profile and may be useful in the alleviation and treatment of ischemic diseases. Copyright

Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same

A compound having the formula (I) or its salt, hydrate, hydrate salt or solvate: wherein R1to R4independently represent H, halogen, OH, alkoxy, optionally substituted alkyl, aryl, or aralkyl group, R5represents H, optionally substituted alkyl, aryl, or aralkyl group, E1represents O, S, or —NR6, where R6represents H, an optionally substituted alkyl, aryl, or aralkyl group, E2represents O, S, or —NR7, where R7represents H, an optionally substituted alkyl, aryl, or aralkyl group, A represents CH, C(OH), or N, X represents H, halogen, alkoxy, or an optionally substituted alkyl group, and Q represents an optionally substituted phenyl group, phenoxy, phenylmethyl, or cycloalkyloxy group, where when E1represents O or S, E2does not represent O or S, which has an action of suppressing the cytotoxic Ca2+overload and lipid peroxidation and effective for pharmaceutical preparation for the alleviation and treatment of symptoms due to ischemic diseases, etc.

Medicament for the alleviation or treatment of symptom derived from ischemic disease and compound useful therefor

PCT No. PCT/JP96/00119 Sec. 371 Date Sep. 23, 1996 Sec. 102(e) Date Sep. 23, 1996 PCT Filed Jan. 23, 1996 PCT Pub. No. WO96/22977 PCT Pub. Date Aug. 1, 1996A medicine having the following basic structure, for the alleviation or treatment of symptoms derived from ischemic diseases and seizures, epilepsy, and migraine, having a powerful action in suppressing cytotoxic Ca2+ overload and free from side-effects: wherein Z=C, CH, or N, X=O or CH2, E and Y=H, OH, a halogen, alkoxy, alkyl, or a halogen-substituted alkyl.

A novel class of Na+ and Ca2+ channel dual blockers with highly potent anti-ischemic effects

A series of novel arylpiperidines (4a-d) which have highly potent blocking effects for both neuronal Na+ and T-type Ca2+ channels with extremely low affinity for dopamine D2 receptors were synthesized. Among these compounds, 1-(2-hydroxy-3-phenoxy)propyl-4-(4-phenoxyphenyl)-piperidine hydrochloride (4c; SUN N5030) exhibited remarkable neuroprotective activity in a transient middle cerebral artery occlusion (MCAO) model.

Arylpiperidine and arylpiperazine derivatives and medicament containing the same

The compound of the formula (I) or its salt or a medicament containing the same STR1 wherein, A and B represent a carbonyl group or sulfonyl group, m and p are different and represent 0 or 1, R1 and R2 may be the same or different from each other and represent a hydrogen atom, an unsubstituted or substituted alkyl group, an unsubstituted or substituted aryl group, an unsubstituted or substituted aralkyl group, an unsubstituted or substituted heterocyclic group containing nitrogen or an unsubstituted or substituted heterocyclic group containing oxygen, or R1 and R2, taken together with the nitrogen atom to which they are linked, may form an unsubstituted or substituted heterocyclic group, provided that when B is a sulfonyl group, R2 does not represent a hydrogen atom, n is an integer of 1 to 6, X represents a methylene group or an oxygen atom, E and Y may be the same or different from each other and represent a hydrogen atom, a halogen atom, an alkoxy group, or an alkyl group which may be substituted by a halogen atom the dotted line shows the presence or absence of a bond, when said dotted line shows the presence of a bond, Z represents a carbon atom, and when said dotted line shows the absence of a bond, Z represents CH or a nitrogen atom.

Inhibitors of protein farnesyltransferase and squalene synthase

The present invention provides a compound of the formula STR1 or a pharmaceutically acceptable salt thereof, which are useful in inhibiting protein farnesyltransferase and the farnesylation of the oncogene protein Ras or inhibiting de novo squalene production resulting in the inhibition of cholesterol biosynthesis, processes for the preparation of the compounds of the invention in addition to intermediates useful in these processes, a pharmaceutical composition, and to methods of using such compounds.